Emflaza

Chemical Namedeflazacort
Dosage FormTablet (oral; 6 mg, 18 mg, 30 mg, 36 mg) Oral suspension (oral; 22.75 mg/ml)
Drug ClassCorticosteroids
SystemMusculoskeletal
CompanyPTC Therapeutics, Inc.
Approval Year2017

Indication

  • To treat Duchenne muscular dystropy in patients ≥ 5 years of age.
Last updated on 10/20/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Emflaza (deflazacort) Prescribing Information 2017PTC Therapeutics, Inc., South Plainfield, NJ
Document TitleYearSource
Corticosteroids for the treatment of Duchenne muscular dystrophy. 2016The Cochrane Database of Systematic Reviews